Multimorbidity and Serological Response to SARS-CoV-2 Nine Months after 1st Vaccine Dose: European Cohort of Healthcare Workers—Orchestra Project
Concepción Violán,
Lucía A. Carrasco-Ribelles,
Giulia Collatuzzo,
Giorgia Ditano,
Mahsa Abedini,
Christian Janke,
Christina Reinkemeyer,
Le Thi Thu Giang,
Filippo Liviero,
Maria Luisa Scapellato,
Marcella Mauro,
Francesca Rui,
Stefano Porru,
Gianluca Spiteri,
Maria Grazia Lourdes Monaco,
Angela Carta,
Marina Otelea,
Agripina Rascu,
Eleonóra Fabiánová,
Zuzana Klöslová,
Paolo Boffetta,
Pere Torán-Monserrat
Affiliations
Concepción Violán
Unitat de Suport a la Recerca Metropolitana Nord, Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mare de Déu de Guadalupe, 08303 Mataró, Spain
Lucía A. Carrasco-Ribelles
Unitat de Suport a la Recerca Metropolitana Nord, Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mare de Déu de Guadalupe, 08303 Mataró, Spain
Giulia Collatuzzo
Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy
Giorgia Ditano
Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy
Mahsa Abedini
Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy
Christian Janke
Division of Infectious Diseases and Tropical Medicine, LMU Klinikum, Leopoldstraße 5, 80802 Munich, Germany
Christina Reinkemeyer
Division of Infectious Diseases and Tropical Medicine, LMU Klinikum, Leopoldstraße 5, 80802 Munich, Germany
Le Thi Thu Giang
Department of Pediatrics, Dr. von Hauner Children’s Hospital, University Hospital, LMU Munich, Lindwurmstrasse 4, 80337 Munich, Germany
Filippo Liviero
Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy
Maria Luisa Scapellato
Occupational Medicine Unit, University Hospital of Padova, 35128 Padova, Italy
Marcella Mauro
Unit of Occupational Medicine, Department of Medical Sciences, University of Trieste, 34129 Trieste, Italy
Francesca Rui
Unit of Occupational Medicine, Department of Medical Sciences, University of Trieste, 34129 Trieste, Italy
Stefano Porru
Occupational Medicine Unit, University Hospital of Verona, 37134 Verona, Italy
Gianluca Spiteri
Occupational Medicine Unit, University Hospital of Verona, 37134 Verona, Italy
Maria Grazia Lourdes Monaco
Occupational Medicine Unit, University Hospital of Verona, 37134 Verona, Italy
Angela Carta
Occupational Medicine Unit, University Hospital of Verona, 37134 Verona, Italy
Marina Otelea
University of Medicine and Pharmacy “Carol Davila”, 020022 Bucharest, Romania
Agripina Rascu
University of Medicine and Pharmacy “Carol Davila”, 020022 Bucharest, Romania
Eleonóra Fabiánová
Occupational Health Department, Regional Authority of Public Health, 97556 Banská Bystrica, Slovakia
Zuzana Klöslová
Occupational Health Department, Regional Authority of Public Health, 97556 Banská Bystrica, Slovakia
Paolo Boffetta
Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy
Pere Torán-Monserrat
Unitat de Suport a la Recerca Metropolitana Nord, Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mare de Déu de Guadalupe, 08303 Mataró, Spain
Understanding antibody persistence concerning multimorbidity is crucial for vaccination policies. Our goal is to assess the link between multimorbidity and serological response to SARS-CoV-2 nine months post-first vaccine. We analyzed Healthcare Workers (HCWs) from three cohorts from Italy, and one each from Germany, Romania, Slovakia, and Spain. Seven groups of chronic diseases were analyzed. We included 2941 HCWs (78.5% female, 73.4% ≥ 40 years old). Multimorbidity was present in 6.9% of HCWs. The prevalence of each chronic condition ranged between 1.9% (cancer) to 10.3% (allergies). Two regression models were fitted, one considering the chronic conditions groups and the other considering whether HCWs had diseases from ≥2 groups. Multimorbidity was present in 6.9% of HCWs, and higher 9-months post-vaccine anti-S levels were significantly associated with having received three doses of the vaccine (RR = 2.45, CI = 1.92–3.13) and with having a prior COVID-19 infection (RR = 2.30, CI = 2.15–2.46). Conversely, lower levels were associated with higher age (RR = 0.94, CI = 0.91–0.96), more time since the last vaccine dose (RR = 0.95, CI = 0.94–0.96), and multimorbidity (RR = 0.89, CI = 0.80–1.00). Hypertension is significantly associated with lower anti-S levels (RR = 0.87, CI = 0.80–0.95). The serological response to vaccines is more inadequate in individuals with multimorbidity.